Oral amphotericin B for the prevention of Candida bloodstream infection in critically ill children* (original) (raw)
Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis
Pierce Geoghegan
Expert review of anti-infective therapy, 2018
View PDFchevron_right
Amphotericin B in the management of fungal infections in a neonatal intensive care unit: experiences in a teaching hospital
Deirdre Engler
The Southern African Journal of Epidemiology and infection, 2012
View PDFchevron_right
Nebulised amphotericin B to eradicate Candida colonisation from the respiratory tract in critically ill patients receiving selective digestive decontamination: a cohort study
David Ong
Critical Care, 2013
View PDFchevron_right
Invasive candidiasis in pediatric intensive care units
akash deep
Indian Journal of Pediatrics, 2009
View PDFchevron_right
Candida Infections in Surgical Patients Dose Requirements and Toxicity of Amphotericin B
Richard Simmons
Annals of Surgery, 1982
View PDFchevron_right
Is There a Therapeutic or Pharmacokinetic Rationale for Amphotericin B Dosing in Systemic Candida Infections?
Chris Gentry
Annals of Pharmacotherapy, 1996
View PDFchevron_right
Minimum inhibitory concentrations of amphotericin B against Candida krusei isolates from a French teaching hospital laboratory: a retrospective study over 8 years
JL Quesada
Mycoses, 2012
View PDFchevron_right
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
Vijay Yeldandi
Critical Care, 2009
View PDFchevron_right
Candidemia in the Pediatric Intensive Care Unit: What�s Different from Candidemia in Adults?
John Dotis
Current Fungal Infection Reports, 2011
View PDFchevron_right
Epidemiology, risk factors, and therapy of candidemia in pediatric hematological patients
Simone Cesaro
View PDFchevron_right
Invasive candidiasis in pediatric intensive care in Greece: a nationwide study
George Briassoulis
Intensive Care Medicine, 2013
View PDFchevron_right
Incidence of candidaemia and antifungal sensitivity in critically ill patients
Vincenzo Vullo, Maria Mascellino
View PDFchevron_right
New options for treatment of candidaemia in critically ill patients
Grzegorz Kofla
Clinical Microbiology and Infection, 2008
View PDFchevron_right
Failure of Systemic Empirical Treatment with Amphotericin B to Prevent Candidemia in Neutropenic Patients with Cancer
A. Reboli
Clinical Infectious Diseases, 1996
View PDFchevron_right
Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations
Itamar Shalit
Journal of Antimicrobial Chemotherapy, 2003
View PDFchevron_right
Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species
Guillermo Quindós, Emilia Canton
Diagnostic Microbiology and Infectious Disease, 2003
View PDFchevron_right
Antifungal Therapy and Outcomes in Infants With Invasive Candida Infections
Daniel K. Benjamin
The Pediatric Infectious Disease Journal, 2012
View PDFchevron_right
Amphotericin B Colloidal Dispersion for Treatment of Candidemia in Immunocompromised Patients
Vikram Singh
Clinical Infectious Diseases, 1998
View PDFchevron_right
Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study.
Kriton S Filos
View PDFchevron_right
A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants with Invasive Candidiasis
Laura Kovanda
The Pediatric infectious disease journal, 2018
View PDFchevron_right
Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis
Antonio Freire
Pediatric Infectious Disease Journal, 2008
View PDFchevron_right
Management of candidiasis Management of Candida species infections in critically ill patients
Jorge Garbino
The Lancet Infectious Diseases, 2003
View PDFchevron_right
Compassionate use of amphotericin B lipid complex (Abelcet) in life-threatening fungal infections: report of 30 courses
Baudouin Byl
Clinical Microbiology and Infection, 1998
View PDFchevron_right
Risk factors for candidemia mortality in hospitalized children
Gregory Jaeger
Jornal de pediatria, 2016
View PDFchevron_right
Invasive Candida Infections and the Harm From Antibacterial Drugs in Critically Ill Patients
Morten Bestle
Critical Care Medicine, 2015
View PDFchevron_right
Characteristics and risk factors of candidemia in pediatric intensive care unit of a tertiary care children's hospital
Moustafa A Hegazi
2014
View PDFchevron_right
Incidence of Candida in patients admitted to ICU
Jayanthi Abraham
View PDFchevron_right
ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp
Γεώργιος Πετρίκκος
Clinical Microbiology and Infection, 2012
View PDFchevron_right
A Randomized, Double-Blind, Prospective Study of Caspofungin vs. Amphotericin B for the Treatment of Invasive Candidiasis in Newborn Infants
Mahmoud Ismail
Journal of Tropical Pediatrics, 2012
View PDFchevron_right
Renal impairment and Amphotericin B formulations in patients with invasive fungal infections
Bertrand Dupont
Medical Mycology, 2008
View PDFchevron_right
Oral itraconazole in treatment of candidemia in a pediatric intensive care unit
Sunit Singhi
Indian journal of pediatrics, 2004
View PDFchevron_right